Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B. Zivadinov R, et al. Among authors: hayward b. PLoS One. 2014 Mar 13;9(3):e91098. doi: 10.1371/journal.pone.0091098. eCollection 2014. PLoS One. 2014. PMID: 24625687 Free PMC article.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S. Dwyer MG, et al. Among authors: hayward b. BMC Neurol. 2015 Nov 11;15:232. doi: 10.1186/s12883-015-0488-9. BMC Neurol. 2015. PMID: 26559139 Free PMC article. Clinical Trial.
Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: A randomized, single-blind, crossover study.
Mahende MK, Huber E, Kourany-Lefoll E, Ali A, Hayward B, Bezuidenhout D, Bagchus W, Kabanywanyi AM. Mahende MK, et al. Among authors: hayward b. PLoS Negl Trop Dis. 2021 Jun 9;15(6):e0007370. doi: 10.1371/journal.pntd.0007370. eCollection 2021 Jun. PLoS Negl Trop Dis. 2021. PMID: 34106922 Free PMC article. Clinical Trial.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly.
Dwyer MG, Zivadinov R, Markovic-Plese S, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Weinstock-Guttman B, Hayward B, Dangond F. Dwyer MG, et al. Among authors: hayward b. J Neuroimmunol. 2015 Apr 15;281:44-50. doi: 10.1016/j.jneuroim.2015.03.002. Epub 2015 Mar 5. J Neuroimmunol. 2015. PMID: 25867467 Free article. Clinical Trial.
Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
Wray S, Armstrong R, Herrman C, Calkwood J, Cascione M, Watsky E, Hayward B, Mercer B, Dangond F. Wray S, et al. Among authors: hayward b. Expert Opin Drug Deliv. 2011 Dec;8(12):1543-53. doi: 10.1517/17425247.2011.628656. Epub 2011 Oct 27. Expert Opin Drug Deliv. 2011. PMID: 22032264 Clinical Trial.
175 results